Publications by authors named "Rolf Linke"

Claim this Profile
E
Efficacy in patients with -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: analyses from ARCHER 1050.
Xingxiang Pu, Juan Li, Bo Zhang, Jinyao Zhang, Tony S K Mok, Rolf Linke

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Ying Cheng, Tony S Mok, Xiangdong Zhou, Shun Lu, Qing Zhou, Rolf Linke

Lung Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050.
Jean Paty, Rickard Sandin, Arlene Reisman, Yi-Long Wu, Maria Rita Migliorino, Rolf Linke

Future Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer.
Jesús Corral, Tony S Mok, Kazuhiko Nakagawa, Rafael Rosell, Ki Hyeong Lee, Rolf Linke

Future Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Tony S Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Rolf Linke

J Clin Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Rolf Linke

Lancet Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
Lawrence Flaherty, Omid Hamid, Gerald Linette, Lynn Schuchter, Sigrun Hallmeyer, Rolf Linke

Cancer J· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Carolina Reyes, Stacey DaCosta Byfield, Rolf Linke, Sacha Satram-Hoang, April H Teitelbaum

Melanoma Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.
Marion G Ott, Frederik Marmé, Gerhard Moldenhauer, Horst Lindhofer, Michael Hennig, Rolf Linke

Int J Cancer· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Catumaxomab: clinical development and future directions.
Rolf Linke, Anke Klein, Diane Seimetz

MAbs· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of imatinib-resistant CML patients.
Rolf Linke, Wolfram Dempke

Onkologie· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis